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Methaqualone was first synthesized in India in 1951 and developed as a potential anti-
malarial drug. Later its soporific effects were explored. In 1965 the drug was combined with 
an anti-histimine diphenhydramine to produce a more potent sedative/ hypnotic and was 
marketed by Roussel under the name of Mandrax (methaqualone 250 mgm: diphenhydramine 
25 mg.). 
 The first indications of drug abuse were reported within a matter of weeks of Mandrax 
reaching the market, but due to the widespread abuse of barbiturates they went largely 
unnoticed. Now the drug is perhaps only second to Mogadon (nitrazepan) as a non-barbiturate 
sedative/hypnotic in the large quantities prescribed. There are however good reasons why this 
particular drug combination ought to be prescribed by doctors with the utmost care. 
 They are: 
1) One pill a day for two months is likely to produce physical dependence. 
2) Prolonged use of the drug does cause physical tolerance and psychological dependence 
similar to that of barbiturate dependence. 
3) Withdrawal of the drug can result in death. It should be carried out in hospital. Initial 
withdrawal symptoms are headaches and severe cramps followed by convulsions. 
Haemorrhages from the stomach may follow in three to five days. 
4) Dependency symptoms include irritability, sleeplessness, delerium tremens, mania and 
epileptiform attacks. If convulsions are not treated, status epilepticus may develop. 
5) Amongst the adolescent drug misusers Mandrax is known as ‘mandies’ or ‘randy 
mandies’. It has a pleasant high if the subject stays awake and it is reported (as barbiturates 
also are in this group) to have an aphrodisiac effect. Due to the marked incoordination 
produced by Mandrax misusers are known also as ‘wall bangers’ because of their propensity 
for walking into solid structures. 
6) In relatively small overdoses or especially in combination with alcohol it can prove 
fatal even with the best efforts at resuscitation. Prolonged coma and hypotension with small 
overdoses is a feature. 
 Roussel are reported to have stated in relation to the U.K. market that ‘because of the 
abuse problem, we have undertaken no direct promotion of Mandrax for the past two years. In 
1972, we withdrew the 1000 pill pack and are withdrawing the 100 pill pack on May 1. It will 
then be available in packets of 30 to reduce the danger of thefts from chemists and overdoses.  
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We are in favour of tighter controls. Mandrax should be under lock and key in Chemists 
shops.’ In the recent Irish Mims it is noted the price is still quoted for 100 bottles. 
 The Department of Health has all drugs which may be liable to abuse, including this 
particular drug under scrutiny and when the new Misuse of Drugs Bill becomes operative as 
an Act there will be provision for reclassification of any drug if this is thought to be desirable. 
 In the Drug Advisory and Treatment Centre and in the Casualty Department of Jervis 
Street Hospital, this particular drug together with the barbiturates causes most concern in the 
overdose cases. 
 The drug is also marketed under the following names—Lancesommal, Matthodorm 
Paldona, Paxidorni, Melsed, Quaalude, Revennal and Sedaquin. 
 Mandrax is sold in tablet and capsule forms. The tablet is white—marked Mx on the 
face and R/L on the reverse. 
The capsule which is the same strength as the tablet is dark and bright blue marked 
Mx/RL. 
Drug abusers in Ireland misuse Mandrax by both the oral and the intravenous routes. 
ADDENDUM 
Since writing this I have now come across a letter by Dr William Sergeant of St Thomas’s 
Hospital, London, on page 716, of the British Medical Journal—23.6.73. 
 It would seem fair to me to make some comment on his views of the selected use of 
drugs which are liable to abuse. One can quite easily understand that he may prefer the drug 
Mandrax in prolonged states of narcosis, with or without intensive electro-convulsive therapy, 
but as he rightly points out—’If one uses Mandrax or Mogadon, one should give only one 
tablet, if possible, as a sedative at night’ … one can also start with Mogadon, and use 
Mandrax, if the former does not work, preferred often to the barbiturates. One must agree 
with Dr Sergeant when he advocates the skilled, selective, clinical use of drugs. 
 One final comment, Dr Sergeant’s patients are a vastly different group from the very 
young, inadequate drug abusers which are seen at the special Drug Treatment Centres in the 
Republic of Ireland and the United Kingdom, and whilst I am not advocating a ban on a 
useful drug, I am merely suggesting that fewer and smaller prescriptions of the drugs, plus 
more drug education, plus more locked cupboards might help us with the co-operation of the 
very responsible Pharmaceutical Company, to avoid Medical Drug Casualties in the very 
young. 
